Skip to main content

Table 1 Baseline demographics and migraine disease characteristics by preventive treatment eligibility status

From: A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe

Demographics US   EUa    Total (US + EU)
  Preventive Eligibleb Preventive Non- Eligiblec Preventive Eligibleb Preventive Non- Eligiblec Preventive Eligibleb Preventive Non- Eligiblec
n = 584 n = 789 n = 1942 n = 2147 n = 2526 n = 2936
Age (years), mean (SD) 41.3 (14.2) 41.1 (14.6) 39.7 (13.4) 39.7 (14.4) 40.1 (13.6) 40.1 (14.5)
Female, % 77.6 72.5* 69.3 70.6 71.2 71.1
White/Caucasian, % 77.6 73.5 90.6 91.8 87.6 86.9
Patient employment status (%)*
 Working full time 55.8 62.2 51.3 51.8 52.4 54.6
 Working part time 9.8 11.4 10.9 10.0 10.6 10.4
 Retired 6.3 6.1 6.7 7.6 6.6 7.2
 Unemployed 4.3 1.6 5.7 5.8 5.4 4.7
 On long-term sick leave 1.9 0.4 1.8 0.7 1.8 0.6
Number of migraine headache days/month (%)
 0–3 0 100.0 0 100.0 0 100.0
 4–7 59.2 0 70.8 0 68.1 0
 8–14 27.2 0 22.6 0 23.6 0
 15+ 13.5 0 6.7 0 8.3 0
Concomitant conditions, %
 Depression 21.9 17.0* 11.9 9.7* 14.3 11.6**
 Anxiety 27.9 22.9* 20.2 18.7 22.0 19.9
 Stress 15.8 15.3 14.1 15.1 14.5 15.2
Migraine condition ever forced them to reduce hours worked n = 383 n = 581 n = 1209 n = 1327 n = 1592 n = 1908
 Yes (%)** 29.0 17.2 24.7 19.5 25.8 18.8
Average migraine severity over the last 3 months, n = 575 n = 783 n = 1922 n = 2117 n = 2497 n = 2900
 Mean (SD) (1 = very mild, 10 = severe) 6.4 (2.1) 5.2 (2.1) 6.1 (1.7) 5.2 (2.0) 6.2 (1.8) 5.2 (2.0)
Patient refractory to preventive medication n = 305 n = 271 n = 810 n = 640 n = 1115 n = 911
 Yes (%)**d 8.2 1.5 9.3 3.6 9.0 3.0
Current preventive therapy, % (most frequent) n = 584 n = 788 n = 1941 n = 2147 n = 2525 n = 2935
 No preventive drug treatment 49.0 66.8 59.1 71.1 56.8 69.9
 Anticonvulsants 26.7 14.7 10.6 7.3** 14.3 9.3
 Antidepressants/ anxiolytics/ benzodiazepines 12.8 6.3 9.5 5.9 10.3 6.0
 Beta blockers 10.8 10.2 15.1 11.3** 14.1 11.0**
  1. p < 0.0001; **p < 0.01; *p < 0.05 for comparisons between preventive eligible and preventive non-eligible
  2. aEuropean (EU) countries included: Germany, France, Spain, Italy and, the UK
  3. bPreventive Eligible was defined as > 4 migraine headache days/month. cPreventive Non-Eligible was defined as > 4 migraine headache days/month
  4. dPatients who are currently receiving a preventive treatment
  5. Abbreviations: SD Standard deviation